NovoCure (NVCR) Non-Current Deffered Revenue (2014 - 2023)

NovoCure's Non-Current Deffered Revenue history runs 9 years deep, the most recent figure standing at $807000.0 for Q2 2023.

• In Q2 2023, Non-Current Deffered Revenue fell 82.23% year-over-year to $807000.0; the TTM figure through Jun 2023 stood at $807000.0 (down 82.23% YoY), while the FY2022 annual figure was $2.9 million, down 55.57% from the prior year.
• Non-Current Deffered Revenue came in at $807000.0 for Q2 2023 at NovoCure, down from $1.8 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $12.1 million in Q4 2020 to a low of $807000.0 in Q2 2023.
• A 5-year average of $7.0 million and a median of $7.9 million in 2019 frame the typical range for Non-Current Deffered Revenue.
• Across the five-year window, Non-Current Deffered Revenue surged 55.49% in 2020 and plunged 82.23% in 2023, its largest moves.
• NovoCure's Non-Current Deffered Revenue stood at $7.8 million in 2019, then soared by 55.49% to $12.1 million in 2020, then tumbled by 46.64% to $6.5 million in 2021, then sank by 55.57% to $2.9 million in 2022, then sank by 71.96% to $807000.0 in 2023.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $807000.0, $1.8 million, and $2.9 million for Q2 2023, Q1 2023, and Q4 2022 respectively.

Peer Comparison